

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
14 November 2024 (14.11.2024)



(10) International Publication Number
WO 2024/229505 A1

(51) International Patent Classification:

A61K 31/7125 (2006.01) A61P 11/00 (2006.01)
A61K 9/00 (2006.01) C12N 15/113 (2010.01)

DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:

PCT/AU2023/050961

(22) International Filing Date:

05 October 2023 (05.10.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

2023901365 05 May 2023 (05.05.2023) AU

Declarations under Rule 4.17:

— of inventorship (Rule 4.17(iv))

Published:

— with international search report (Art. 21(3))
— with sequence listing part of description (Rule 5.2(a))
— in black and white; the international application as filed
contained color or greyscale and is available for download
from PATENTSCOPE

(71) Applicant: RAGE BIOTECH PTY LTD [AU/AU]; Level
35, 360 Elizabeth Street, Melbourne, Victoria 3000 (AU).

(72) Inventors: THOMAS, Merlin Christopher; c/- Level
35, 360 Elizabeth Street, Melbourne, Victoria 3000 (AU).
PICKERING, Raelene Jane; c/- Level 35, 360 Elizabeth
Street, Melbourne, Victoria 3000 (AU).

(74) Agent: FPA PATENT ATTORNEYS PTY LTD; Level
19, South Tower, 80 Collins Street, Melbourne, Victoria
3000 (AU).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,

(54) Title: ADMINISTRATION OF OLIGONUCLEOTIDES

(57) Abstract: The present invention relates to methods for the modulation of alternative splicing of pre-mRNA coding for the Receptor for Advanced Glycation End-products (RAGE) or part thereof, using antisense oligonucleotides (AONs) to modify the expression and/or activity of RAGE isoforms. In one aspect, the present invention provides a method for promoting the production of endogenous soluble RAGE and/or reducing the production of membrane bound RAGE (mRAGE) in a subject, the method comprising: in a first administration, administering to the respiratory tract of the subject an antisense oligonucleotide (AON) that promotes the production of endogenous soluble RAGE and/or reduces the production of membrane bound RAGE (mRAGE), in a second administration, administering to the respiratory tract of the subject an AON that promotes the production of endogenous soluble RAGE and/or reduces the production of membrane bound RAGE (mRAGE), wherein the second administration is at least about 7 days after the first administration, thereby promoting the production of endogenous soluble RAGE and/or reducing the production of membrane bound RAGE (mRAGE) in the subject.

WO 2024/229505 A1